Edmond DE Rothschild Holding S.A. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Edmond DE Rothschild Holding S.A. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 7.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,106,110 shares of the biopharmaceutical company’s stock after selling 163,621 shares during the period. Pfizer comprises approximately 1.0% of Edmond DE Rothschild Holding S.A.’s holdings, making the stock its 22nd biggest holding. Edmond DE Rothschild Holding S.A.’s holdings in Pfizer were worth $55,875,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several analyst reports. UBS Group decreased their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

Shares of PFE stock opened at $25.20 on Monday. The company has a market cap of $142.93 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The business has a 50 day moving average of $26.06 and a two-hundred day moving average of $26.90. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.